Publications by authors named "E Chuluyan"
Pancreatic cancer is highly lethal and has limited treatment options available. Our team had previously developed ZZW-115, a promising drug candidate that targets the nuclear protein 1 (NUPR1), which is involved in pancreatic cancer development and progression. However, clinical translation of ZZW-115 was hindered due to potential cardiotoxicity caused by its interaction with the human Ether-à-go-go-Related Gene (hERG) potassium channel.
View Article and Find Full Text PDFThe excessive demand for organ transplants has promoted the development of strategies that increase the supply of immune compatible organs, such as xenotransplantation of genetically modified pig organs and the generation of bioartificial organs. We describe a method for the partial replacement of rat endothelial cells for human endothelial cells in a rat's kidney, obtaining as a final result a rat-human bioartificial kidney. First, in order to maintain parenchymal epithelial cells and selectively eliminate rat endothelial cells, three methods were evaluated in which different solutions were perfused through the renal artery: 0.
View Article and Find Full Text PDFArticle Synopsis
- The interaction between tumor cells and their surrounding microenvironment is crucial for the progression of pancreatic ductal adenocarcinoma (PDAC) and presents potential therapeutic targets.
- REG3β, a factor produced by the tumor's far microenvironment, promotes PDAC growth, and targeting it with specific antibodies can limit tumor expansion in mice models.
- The study further reveals that REG3β activates CTGF, and inhibiting REG3β reduces CTGF levels, indicating that REG3β's effect on PDAC progression is mediated by CTGF over-activation, suggesting REG3β as a promising target for PDAC treatment.